Contact us

Using the power of metabolism to treat cancer

Faeth was founded by a team of world-leading scientists to bring metabolically-driven cancer treatments to patients. Faeth’s programs span across multiple tumor types and leverage our knowledge of human and tumor metabolism to increase the efficacy of our cancer drugs.

Groundbreaking research led by Faeth’s founders show that by precisely modulating nutrients, we can alter the tumor and systemic metabolism to favorably impact cancer drugs.

HubSpot Video


Faeth’s therapeutic programs combine traditional anti-cancer drugs with precision nutrition diets designed to increase the efficacy of the drugs.
Our lead program, FTH-001, targets the Pi3K/mTOR pathway, the most frequently mutated pathway in solid tumors. This pathway regulates cell growth and metabolism, and drives cancer proliferation. To date, efforts to inhibit this pathway have been unsuccessful and lead to unacceptable patient toxicities.

FTH-001 addresses common issues with PI3K/mTOR inhibitors

FTH-001 targets multiple pathway components to completely shutdown the mTOR/PI3K pathway. The program also includes an insulin suppressing diet, designed to mitigate the toxicities commonly associated with the drug class.

Preclinical data shows dramatic impact of combining PI3K inhibitor with an insulin suppressing diet

Early clinical development for FTH-001@2x
Early clinical development for FTH-001 is focused on endometrial cancer.


Faeth’s FTH-002 program combines our FTH-002 therapeutic with metabolic optimization through diet to deprive tumors of the nutrients they need to grow.

FTH-002 combination outperforms impact of radiotherapy alone

Falcone et al Br J Cancer. 2022, 127(10): 1773–1786. Maddocks et al Nature 2017, 544; 372–376
Metabolic Optimization Only
Radiotherapy Only
Radiotherapy + Metabolic Optimization
Apoptotic marker:
cleaved cascade-3
Science Image

Our preclinical research has shown that restricting serine and glycine can significantly improve survival, doubling the 12-month survival rate in one model from 25% to 50%.

Mask Group 4

Early clinical development for FTH-002 is focused on pancreatic cancer.